INNATE PHARMA SA (IPH.PA) Stock Price, Forecast & Analysis
EPA:IPH • FR0010331421
IPH.PA Key Statistics, Chart & Performance
The current stock price of IPH.PA is 1.5 EUR. In the past month the price increased by 0.13%. In the past year, price decreased by -29.88%.
IPH.PA Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to IPH.PA. When comparing the yearly performance of all stocks, IPH.PA is a bad performer in the overall market: 90.56% of all stocks are doing better.
IPH.PA Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to IPH.PA. IPH.PA has a bad profitability rating. Also its financial health evaluation is rather negative.
IPH.PA Financial Highlights
Over the last trailing twelve months IPH.PA reported a non-GAAP Earnings per Share(EPS) of -0.55. The EPS decreased by -30.42% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -49.55% | ||
| ROE | -895.24% | ||
| Debt/Equity | 3.52 |
IPH.PA Forecast & Estimates
8 analysts have analysed IPH.PA and the average price target is 6.27 EUR. This implies a price increase of 318.2% is expected in the next year compared to the current price of 1.5.
For the next year, analysts expect an EPS growth of -35.8% and a revenue growth -26.21% for IPH.PA
IPH.PA Ownership
IPH.PA Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| 1AE | ARGENX SE | 27.91 | 43.962B | ||
| ARGX | ARGENX SE | 27.78 | 43.888B | ||
| 22UA | BIONTECH SE-ADR | N/A | 22.579B | ||
| ABVX | ABIVAX SA | N/A | 8.651B | ||
| 2X1 | ABIVAX SA | N/A | 8.619B | ||
| GXE | GALAPAGOS NV | N/A | 1.957B | ||
| GLPG | GALAPAGOS NV | N/A | 1.948B | ||
| IVA | INVENTIVA SA | N/A | 1.18B | ||
| 6IV | INVENTIVA SA | N/A | 1.174B | ||
| NANO | NANOBIOTIX | N/A | 1.048B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Euronext Paris Exchange | Find stocks with similar TA and Setup ratings on the EuroNext exchanges | Find stocks with similar Fundamental rating on the EuroNext exchanges | Find the competitors with the best technical ratings on the EuroNext exchanges | Find the competitors with the best fundamentals on the EuroNext exchanges | Find the competitors with the best valuation on the EuroNext exchanges | Find the competitors with the best dividend on the EuroNext exchanges | Find the competitors with the best analyst ratings on the EuroNext exchanges
About IPH.PA
Company Profile
Innate Pharma SA is a global, clinical-stage biotechnology company, which engages in developing immunotherapies for cancer patients. The company is headquartered in Marseille, Paca and currently employs 181 full-time employees. The company went IPO on 2006-10-31. The firm identifies and characterizes drug candidates, selects indications, and manages the pre-clinical and clinical development of products. Innate Pharma primarily focuses on the development of new therapeutic solutions and monoclonal antibodies for the treatment of cancer, as well as for the treatment of infectious diseases and chronic inflammatory pathologies. The firm develops two categories of immunotherapies: immuno-modulators and cytotoxic antibodies. The company works in collaboration with Bristol-Myers Squibb for Phase I cancer antibody program and with Novo Nordisk A/S for two antibody programs in inflammation treatment. The firm operates through anti-NKG2A antibody, an immune checkpoint inhibitor ready for Phase II development in oncology from Novo Nordisk. The company also has a multi-product partnership with AstraZeneca.
Company Info
INNATE PHARMA SA
117 avenue de Luminy, Bp 30191
Marseille PACA FR
Employees: 181
Phone: 33430303030
INNATE PHARMA SA / IPH.PA FAQ
Can you describe the business of INNATE PHARMA SA?
Innate Pharma SA is a global, clinical-stage biotechnology company, which engages in developing immunotherapies for cancer patients. The company is headquartered in Marseille, Paca and currently employs 181 full-time employees. The company went IPO on 2006-10-31. The firm identifies and characterizes drug candidates, selects indications, and manages the pre-clinical and clinical development of products. Innate Pharma primarily focuses on the development of new therapeutic solutions and monoclonal antibodies for the treatment of cancer, as well as for the treatment of infectious diseases and chronic inflammatory pathologies. The firm develops two categories of immunotherapies: immuno-modulators and cytotoxic antibodies. The company works in collaboration with Bristol-Myers Squibb for Phase I cancer antibody program and with Novo Nordisk A/S for two antibody programs in inflammation treatment. The firm operates through anti-NKG2A antibody, an immune checkpoint inhibitor ready for Phase II development in oncology from Novo Nordisk. The company also has a multi-product partnership with AstraZeneca.
What is the current price of IPH stock?
The current stock price of IPH.PA is 1.5 EUR. The price increased by 0.67% in the last trading session.
Does INNATE PHARMA SA pay dividends?
IPH.PA does not pay a dividend.
What is the ChartMill rating of INNATE PHARMA SA stock?
IPH.PA has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
What is the analyst forecast for IPH.PA stock?
8 analysts have analysed IPH.PA and the average price target is 6.27 EUR. This implies a price increase of 318.2% is expected in the next year compared to the current price of 1.5.
Can you provide the PE ratio for IPH stock?
INNATE PHARMA SA (IPH.PA) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.55).
What is INNATE PHARMA SA worth?
INNATE PHARMA SA (IPH.PA) has a market capitalization of 140.56M EUR. This makes IPH.PA a Micro Cap stock.